Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Immutep Ltd is a biotechnology company headquartered in Australia that focuses on personalised bio-therapeutic products for cancer.
|19 Jan 2022||$0.45||$-0.01||-2.20%||3,402,936||$0.44||$0.46||$0.44|
|18 Jan 2022||$0.46||$0.01||2.22%||611,470||$0.46||$0.47||$0.45|
|17 Jan 2022||$0.45||$-0.01||-2.20%||983,708||$0.45||$0.46||$0.45|
|14 Jan 2022||$0.46||$-0.02||-4.26%||1,434,959||$0.46||$0.47||$0.45|
|13 Jan 2022||$0.47||$-0.01||-2.11%||1,213,245||$0.47||$0.47||$0.46|
|12 Jan 2022||$0.48||$0.02||4.35%||1,181,690||$0.46||$0.48||$0.46|
|11 Jan 2022||$0.46||$-0.02||-4.17%||1,595,278||$0.48||$0.48||$0.46|
|10 Jan 2022||$0.48||$0.01||2.11%||1,176,134||$0.48||$0.49||$0.46|
|07 Jan 2022||$0.48||$0.00||0.00%||1,205,678||$0.48||$0.48||$0.46|
|06 Jan 2022||$0.48||$-0.03||-5.94%||3,473,499||$0.50||$0.50||$0.47|
|05 Jan 2022||$0.51||$0.00||0.00%||1,279,050||$0.51||$0.52||$0.50|
|04 Jan 2022||$0.51||$0.02||4.08%||2,115,518||$0.50||$0.52||$0.49|
|31 Dec 2021||$0.49||$0.00||0.00%||1,094,749||$0.49||$0.50||$0.49|
|30 Dec 2021||$0.49||$0.00||0.00%||2,312,408||$0.49||$0.50||$0.48|
|29 Dec 2021||$0.49||$-0.01||-2.00%||2,382,841||$0.50||$0.51||$0.49|
|24 Dec 2021||$0.50||$0.01||2.02%||1,260,503||$0.50||$0.51||$0.49|
|23 Dec 2021||$0.50||$0.01||2.04%||1,420,255||$0.49||$0.50||$0.48|
|22 Dec 2021||$0.49||$0.01||2.08%||1,114,333||$0.49||$0.50||$0.48|
|21 Dec 2021||$0.48||$0.02||4.35%||859,259||$0.46||$0.49||$0.46|
|01 Dec 2021||Russell Howard||Exercise||250||$118,750||
Conversion of securities.
|01 Dec 2021||Russell Howard||Issued||339||$161,319||
Issue of securities. 339,621 - Director Performance Rights
|01 Dec 2021||Russell Howard||Buy||250||$118,750||
Conversion of securities.
|01 Dec 2021||Marc Voigt||Issued||3||$1,710,000||
Issue of securities. 6,000,000 - Performance Rights
|04 Oct 2021||Grant Chamberlain||Buy||450||$240,750||
Conversion of securities.
|04 Oct 2021||Grant Chamberlain||Exercise||450||$240,750||
Conversion of securities. 900,000 - Performance Rights
|04 Oct 2021||Pete Meyers||Exercise||500||$267,500||
Conversion of securities. 1,000,000 - Performance Rights
|04 Oct 2021||Pete Meyers||Buy||500||$267,500||
Conversion of securities.
|Dr Russell J Howard||Non-Executive ChairmanNon-Executive Director||May 2013||
Dr Howard is an Australian scientist, executive manager, and entrepreneur. He was a pioneer in molecular parasitology and commercialisation of DNA Shuffling. He is an inventor of 9 patents and has over 140 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr Howard worked at Schering Plough's DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin out from GlaxoWellcome, as Maxygen's CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products over 12 years of his tenure as CEO. After leaving Maxygen in 2008, he started the Cleantech company NovoNutrients Inc. (formerly Oakbio, Inc.) and remains involved in several innovative companies in the USA and Australia. He is currently Executive Chairman of NeuClone Pty Ltd.
|Mr Pete A Meyers||Non-Executive Deputy ChairmanNon-Executive Director||Feb 2014||
Mr Meyers is the Chief Financial Officer of Slayback Pharma LLC. Prior to joining Slayback, Mr Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation. Prior to his role at TetraLogic, Mr Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as CoHead of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr Meyers is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and serves on the Board of Directors of East End Hospice, Inc.
|Mr Marc Voigt||Chief Financial OfficerChief Executive OfficerExecutive Director||May 2012||
Mr Voigt has more than 21 years of experience in the financial and biotech industry, having joined the Immutep team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Immutep 's Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net.IPO AG, a publicly listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. He then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specialising in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds. Since 2001, he has been a judge and coach in BPW, Germany's largest regional start-up initiative.
|Mr Grant Chamberlain||Non-Executive Director||Aug 2017||
Mr Chamberlain is a partner of One Ventures, one of Australia's leading venture capital firms. Prior to joining OneVentures in 2017 Mr Chamberlain was Head of Mergers & Acquisitions and Financial Sponsors Australia at Bank of America Merrill Lynch. Prior to joining Bank of America Merrill Lynch in 2013, Mr Chamberlain held senior positions at Nomura Australia and Deutsche Bank. He has over 20 years' experience in investment banking and advised on many of the largest mergers and acquisitions transactions in Australia during that time. He began his career as a corporate lawyer at Freehill Hollingdale & Page.
|Ms Deanne Miller||Chief Operating OfficerCompany SecretaryGeneral Counsel||
|Ms Indira Naidu||Joint Company Secretary||Jan 2021||
|Deanne Miller||Chief Operating OfficerCompany SecretaryGeneral Counsel||
|Dr Frederic Triebel||Chief Scientific Officer & Chief Medical Officer||
|Indira Naidu||Joint Company Secretary||
|HSBC Custody Nominees (Australia) Limited||324,272,007||38.11%|
|National Nominees Limited||60,483,220||7.11%|
|Citicorp Nominees Pty Limited||43,042,850||5.06%|
|J P Morgan Nominees Australia Pty Limited||31,044,298||3.65%|
|Cs Third Nominees Pty Limited <HSBC Cust Nom Au Ltd 13 A/C>||20,082,579||2.36%|
|BNP Paribas Noms Pty Ltd <DRP>||13,932,786||1.64%|
|HSBC Custody Nominees (Australia) Limited A/C 2||9,678,956||1.14%|
|UBS Nominees Pty Ltd||7,199,156||0.85%|
|BNP Paribas Nominees Pty Ltd Acf Clearstream||6,235,332||0.73%|
|Sandhurst Trustees Ltd <Endeavor Asset Mgmt Mda A/C>||5,499,923||0.65%|
|Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp>||4,501,767||0.53%|
|Brispot Nominees Pty Ltd <House Head Nominee A/C>||4,456,012||0.52%|
|Macenrock Pty Ltd <Macenrock S/F A/C>||3,622,897||0.43%|
|Ms Lucy Turnbull||2,981,626||0.35%|
|M & Hc Pty Ltd <Caudle Investment A/C>||2,314,372||0.27%|
|Mr Thomas Tscherepko||2,300,000||0.27%|
|Mr David Stewart Field||2,270,000||0.27%|